Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform
Genentech is adding a new trial using Syndax’s lead drug entinostat to its platform for testing new drug combinations with its PD-L1 drug Tecentriq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
